Diabetes is now considered an important risk factor for cardiovascular disease, and a complex interplay of pathogenic factors complicates management of both diseases.
EASD 2018 Following a review of the latest evidence, the EASD and the ADA introduced new recommendations on managing hyperglycemia in T2DM, including specific drug classes for some patients and enhancing medication adherence.
EASD 2018 Increased fasting glucose, higher BMI and impaired insulin sensitivity were detectable up to 10 years before the diagnosis of diabetes as well as prediabetes.
EASD 2018 Weight gain between the age of 10 and adulthood is associated with T2DM risk. Overweight children at age 10 appear to be at lower risk for developing T2DM than children who are regular weight at age 10 and then later become overweight as adults.
EASD 2018 A study found various clinical and biochemical factors that are associated with a greater risk of fast disease progression in T2DM patients.
ESC 2018 In overweight or obese patients with CVD or diabetes with one CV risk factor, lorcaserin demonstrated to be safe with respect to CV outcomes. Dr. Bohula discussed the implications of the CAMELLIA-TIMI 61 trial.
ESC 2018 Although aspirin resulted in a reduction of CV events in a primary prevention setting of diabetes patients, this CV benefit was counterbalanced by an increase in bleeding.
ESC 2018 Use of omega-3 fatty acid supplements did not result in reduction of CV outcomes in the ASCEND trial, a large, randomized, long-term trial of diabetes patients.
ESC 2018 One large randomized trial showed that use of aspirin for primary prevention reduced CV events in a diabetes population but at the cost of bleeding, and another resulted in no CV benefit in patients with moderate CV risk.
ESC 2018 The randomized ASCEND clinical trial showed no beneficial effects of omega-3 fatty acids intake on serious vascular events and all-cause or cause-specific mortality in diabetic patients.
This is a summary of the presentation by prof. Rydén, in which he reviews cardiovascular outcome trials with different types of GLP-1 RAs and explains the differences.
This summary of the presentation by prof. Hobbs illustrates why diabetes poses a high burden to primary health care, since patients with T2DM are at high CV risk. This risk can be lowered by targeting various risk factors.
Prof. Rydén reviews cardiovascular outcome trials with different types of GLP-1 RAs and explains the differences.